Table 2.

Summary of assays and response rates in immune checkpoint inhibitor trials.

Drug		Antiboy for PD-L1 IHC assay	Definition of PD-L1 positivity
Nivolumab (SA)	PD-1	Rabbit 28-8 (Dako)	PD-L1 ≥5% (TC)
Atezolizumab (SA)	PD-L1	Rabbit SP142 (Ventana)	IHC 1/2/3 (IC)
Nivolumab/Ipilimumab(C)	PD-1/CTLA-4	Rabbit 28-8 (Dako)	PD-L1 ≥1% (TC)
Atezolizumab/Bevacizumab (C)	PD-L1/antiVEGF	Rabbit SP142 (Ventana)	IHC 1/2/3 (IC)

Locally advanced or in metastatic renal cell carcinoma.

TC, tumor cells; IC, immuno cells in the microenvironment; SA, single agent; C, combination of agents; IHC 1/2/3: IHC1 is ≥1%, IHC2 is ≥5%, IHC3 is ≥10%.